Network News
A key factor in the success of an organ transplant is the condition of the donated organ at the time of implantation. Preserving the organ prior to transplantation using machine perfusion plays a crucial role in this process. This procedure has now been implemented particularly efficiently at Heidelberg University Hospital (UKHD): as part of a […]
read more
Award-winning: Concept for “the perfect stroke room”
UKHD wins DGN Nursing Award 2025 for its “Stroke Unit Innovation Room” project. Full Text in German below. Ausgezeichnet: Konzept für „das perfekte Schlaganfallzimmer“ UKHD gewinnt DGN-Pflegepreis 2025 für das Projekt „Innovationszimmer Stroke Unit“ Das Universitätsklinikum Heidelberg (UKHD) ist mit dem Pflegepreis der Deutschen Gesellschaft für Neurologie (DGN) ausgezeichnet worden. Prämiert wurde das Projekt „Innovationszimmer […]
read more
FDA approves Promega OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® in combination with LENVIMA® in advanced endometrial cancer
Promega’s MSI technology will help identify patients with microsatellite stable (MSS) endometrial cancer Full Text in German below. Die FDA genehmigt das Promega OncoMate® MSI Dx Analysis System als Begleitdiagnostikum für KEYTRUDA® in Kombination mit LENVIMA® bei fortgeschrittenem Endometriumkarzinom Die MSI-Technologie von Promega wird bei der Identifizierung von Patientinnen mit mikrosatellitenstabilem (MSS) Endometriumkarzinom helfen Madison, […]
read more
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
NORTH CHICAGO, Ill., Nov. 18, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R2) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). This approval of […]
read more
Universität Heidelberg with 16 “Highly Cited Researchers”
International evaluation names researchers whose publications have been most cited worldwide 16 researchers from Heidelberg University feature on the recently published list of “Highly Cited Researchers”. This international evaluation names researchers whose publications have been cited most frequently worldwide in their respective field or who have an outstanding track-record of publications across several disciplines. The […]
read more
Universität Heidelberg: New DFG Research Unit in Oncology
GenoMiCC consortium deals with functional genomics and microbiomics in colorectal cancer and is coordinated at the Medical Faculty Mannheim In the latest approval round of the German Research Foundation (DFG), Heidelberg University has been successful with a grant application for a new Research Unit in oncology. The GenoMiCC consortium pursues the goal of identifying new […]
read more
Phylogenetic trees, biodiversity and research policy: “Highly Cited Researcher“ at HITS
For ten years running, computer scientist Alexandros Stamatakis from the Heidelberg Institute for Theoretical Studies (HITS) has been identified as one of the most cited researchers worldwide, according to this year’s “Highly Cited Researchers” list from Clarivate. The ranking is an important indicator for the impact of a researcher’s scientific publications. But Stamatakis is also […]
read more
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Paris and Tarrytown, NY, November 7, 2025. Positive results from the pivotal LIBERTY-AFRS-AIMS phase 3 study (NCT04684524) evaluating the investigational use of Dupixent (dupilumab) in adults and children aged […]
read more
How the biological clock ticks in the female reproductive tract – Breakthrough of the Year Award 2025 for Ângela Gonçalves
Endometriosis, menopause, ovarian cancer – still poorly researched and often misdiagnosed. Ângela Gonçalves combines AI, molecular biology, and clinical findings to develop non-invasive tools for early detection, personalized care, and healthier aging – directly challenging gender bias in medicine. The scientist from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim is the winner […]
read more
